Metformin, cancer, COVID-19, and longevity

Int J Clin Pharmacol Ther. 2023 Mar;61(3):93-95. doi: 10.5414/CP204390.
No abstract available

MeSH terms

  • COVID-19*
  • Diabetes Mellitus, Type 2* / diagnosis
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / epidemiology
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Longevity
  • Metformin* / adverse effects
  • Neoplasms* / drug therapy
  • Neoplasms* / epidemiology

Substances

  • Metformin
  • Hypoglycemic Agents